Interactions of anticancer drugs with usual and mismatch base pairs - Density functional theory studies

Biophysical Chemistry

Volumn 136, Issue 1, 2008, Pages 50-58

  Deepa, P ^a   Kolandaivel, P ^a   Senthilkumar, K ^a  

^a BHARATHIAR UNIVERSITY   (India)

Author keywords

5 fluorouracil; Base pairs; Electron density; Hydrogen bonding; Hydroxyurea; Interaction energy; Natural Bond Orbital analysis

Indexed keywords

FLUOROURACIL; HYDROXYUREA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DENSITY FUNCTIONAL THEORY; HYDROGEN BOND; MISMATCH REPAIR; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BASE PAIR MISMATCH; BASE PAIRING; HYDROGEN BONDING; MODELS, THEORETICAL;

EID: 44349179160     PISSN: 03014622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpc.2008.04.007     Document Type: Article

References (81)

1. Gribble G.W. The Alkaloids (1990), Academic Press, New York
2. Braga S.F., de Melo L.C., and Barone P.M.V.B. Semiempirical study on the electronic structure of antitumor drugs ellipticines, olivacines and isoellipticines. J. Mol. Struct., Theochem 710 (2004) 51-59
3. Sorg B.L., Hull W.E., Kliem H.-C., Mier W., and Wiessler M. Synthesis and NMR characterization of hydroxyurea and mesylglycol glycoconjugates as drug candidates for targeted cancer chemotherapy. Carbohydr. Res. 340 (2005) 181-189
4. Torchilin V.P. Drug targeting. Eur. J. Pharm. Sci. 11 (2000) 81-91
5. Dubowchik G.M., and Walker M.A. Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs - network analysis and mechanistic interpretation. Pharm. Ther. 83 (1999) 67-123
6. B.L. Sorg, W.E. Hull, H-C. Kliem, W. Mier, M. Wiessler, Synthesis and NMR characterization of hydroxyurea and mesylglycol glycoconjugates as drug candidates for targeted cancer chemotherapy, Carbohydr. Res. 340 (2005) 181-189.
7. Donehower R.C. An overview of the clinical experience with Hydroxyurea. Semin. Oncol. 19 (1992) 11-19
8. Friedrisch J.R., Pra D., Maluf S.W., Bittar C.M., Mergener M., Pollo T., Kayser M., da Silva M.A.L., Henriques J.A.P., and Silla L.M.R. DNA damage in blood leukocytes of individuals with sickle cell disease treated with hydroxyurea. Mutat. Res. 649 (2007) 213-220
9. Yarbro J.W. Mechanism of action of hydroxyurea. Semin. Oncol. 19 (1992) 1-10
10. de Montalembert M. Hydroxyurea and other agents stimulating synthesis of fetal hemoglobin. Pathol. Biol. (Paris) 47 (1999) 55-58
11. de Melo E.J., Mayerhoffer R.O., and de Souza W. Hydroxyurea inhibits intracellular Toxoplasma gondii multiplication. FEMS Microbiol. Lett. 185 (2000) 79-82
12. Murphy M.L., and Chaube S. Preliminary survey of Hydroxyurea (Nsc-32065) as a teratogen. Cancer Chemother. Rep. 40 (1964) 1-7
13. Griffith K.M. Hydroxyurea (Nsc-32065): results of a phase I study. Cancer Chemother. Rep. 40 (1964) 33-36
14. Koren A., Segal-Kupershmit D., Zalman L., Levin C., Hana M.A., Dina A.L., and Attias D. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia. Pediatr. Hematol. Oncol. 16 (1999) 221-232
15. Li J.C., and Kaminskas E. Progressive formation of DNA lesions in cultured Ehrlich ascites tumor cells treated with hydroxyurea. Cancer Res. 47 (1987) 2755-2758
16. Balajee A.S., and Geard C.R. Replication protein A and g-H2AX foci assembly is triggered by cellular response to DNA double-strand breaks. Exp. Cell Res. 300 (2004) 320-334
17. Danenberg P.V., Malli H., and Swenson S. Thymidylate synthase inhibitors. Semin. Oncol. 26 (1999) 621-631
18. Wanga W., Collie-Duguida E., and Cassidy J. Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines. FEBS Lett. 531 (2002) 415-420
19. Andre T., Boni C., Mounedji-Boudiaf L., Navarro M., Tabernero J.T., Hickish T., Topham C., Zaninelli M., Philipalingam, Bridgewater J., Tabah-Fisch I., and de Gramont A. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 350 (2004) 2343-2351
20. Carethers J.M., Chauhan D.P., Fink D., Nebel S., Bresalier R.S., Howell S.B., and Boland C.R. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 117 (1999) 123-131
21. Longley D.B., Harkin D.P., and Johnston P.G. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat. Rev., Cancer 3 (2003) 330-338
22. Ribic C.M., Sargent D.J., Moore M.J., Thibodeau S.N., French A.J., Goldberg R.M., Hamilton S.R., Puig P.L., Gryfe R., Shepherd L.E., Tu D., Redston M., and Gallinger S. Tumor micro satellite instability status as a predictor of benefit from fluorouracilbased adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 349 (2003) 247-257
23. Carethers J.M., Smith E.J., Behling C.A., Nguyen L., Tajima A., Doctolero R.T., Cabrera B.L., Tajima A., Doctolero R.T., Cabrera B.L., Goel A., Arnold C.A., Miyai K., and Boland C.R. Use of 5-Fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 126 (2004) 394-401
24. de Vos tot Nederveen Cappel W.H., Meulenbeld H.J., Kleibeuker J.H., Nagengast F.M., Menko F.H., Griffioen G., Cats A., Morreau H., Gelderblom H., and Vasen H.F.A. Survival after adjuvant 5FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. Int. J. Cancer 109 (2004) 468-471
25. Reni M., Cereda S., and Galli L. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) for patients with advanced pancreatic cancer: the ghost regimen. Cancer Lett. 256 (2007) 25-28
26. Warner E., Jensen J.L., Cripps C., Khoo K.E., Goel R., Kerr I.A., Bjarnason G.A., Fields A.L., and Hrincu A. Outpatient 5-fluorouracil, folinic acid and cisplatin in patients with advanced esophageal carcinoma. Acta Oncol. 38 (1999) 255-259
27. de Gramont A., Bosset J.F., Milan C., Bosset J.F., Milan C., Rougier P., Bouche O., Etienne P.L., Morvan F., Louvet C., Guillot T., Francois E., and Bedenne L. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with twice-monthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J. Clin. Oncol. 15 (1997) 808-815
28. Louvet C., de Gramont A., Demuynck B., Nordlinger B., Maisani J.-E., Lagadec B., Delfau S., Varette C., Gonzalez-Canali G., and Krulik M. High-dose folinic acid, 5-fluorouracil bolus and continuous infusion in poor-prognosis patients with advanced measurable gastric cancer. Ann. Oncol. 2 (1991) 229-230
29. Johnston P.G., Geoffrey F., Drake J., Voeller D., Grem J.L., and Allegra C.J. The cellular interaction of 5-fluorouracil and cisplatin in an human colon carcinoma cell line. Eur. J. Cancer 32 (1996) 2148-2154
30. Becouarn Y., Brunet R., and Barbe- Gaston C. Fluorouracill, doxorubicin, cisplatin and altretamine in the treatment of metastatic carcinoma of unknown primary. Eur. J. Cancer Clin. Oncol. 25 (1989) 861-865
31. Jadeja J., Legha S., Burgess M., and Bodey G. Combination chemotherapy with 5-Fu, adriamycin, cyclophosphamide and cis-platinum (FACP) in the treatment of adenocarcinoma of unknown primary (ACUP0 and undifferentiated carcinomas (UCUP). Proc. Am. Soc. Clin. Oncol. 237 (1983) 926 abst. C 2
32. Goldberg R.M., Smith F.P., Ueno W., Ahlgren J.D., and Schein P.S. 5-Fluorouracil, adriamycin and mitomycin in the treatment of adenocarcinoma of unknown primary. J. Clin. Oncol. 4 (1986) 395-399
33. Mans D.R.A., Grivicich I., Peters G.J., and Schwartsmann G. Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines. Eur. J. Cancer 35 (1999) 1851-1861
34. Goldberg R.M., and Erlichman C. Irinotecan plus 5FU and leucovorin in advanced colorectal cancer: North American trials. Oncology (Huntingt) 12 (1998) 59-63
35. Saltz L., Shimada Y., and Khayat D. CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer. Eur. J. Cancer 32 (1996) 24-31
36. Khalaj A., Doroudi A.R., Ostad S.N., Khoshayand M.R., Babaid M., and Adibpour N. Synthesis, aerobic cytotoxicity, and radiosensitizing activity of novel 2,4-dinitrophenylamine tethered 5-fluorouracil and hydroxyurea. Bioorg. Med. Chem. Lett. 16 (2006) 6034-6038
37. Hoshino T., and Nagashima T. Factors modifying cytotoxicity induced by 5FU and hydroxyurea. Cancer Treat. Rep. 69 (1985) 993-997
38. de Gramont A., Louvet C., Bennamoun M., Varette C., Demuynck B., Beerblock K., Moreau S., Soubrane D., Mal F., Grange J.D., Zylberait D., and Krulik M. Dual modulation of 5-fluorouracil with folinic acid and hydroxyurea in metastatic colorectal cancer. J. Infus. Chemother. 6 (1996) 97-101
39. Louvet C., Carrat F., Mal F., Mabro M., Beerblock K., Vaillant J.C., Cady J., André T., Gamelin E., and de Gramont A. Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen). Cancer Investig. 21 (2003) 14-20
40. Raymond E., de Gramont A., Louvet C., Tournigand C., Demuynck B., Beerblock K., Carola E., and Krulik M. Clinical benefit with cisplatin, hydroxyurea and 5-fluorouracil/leucovorin in advanced pancreatic carcinoma. Eur. J. Cancer 33 (1997) 696-697
41. Tai{dotless}eba J., Artru P., Baujat B., Mabro M., Carola E., Maindrault F., Tournigand C., Krulik M., Louvet C., and de Gramont A. Optimisation of 5-fluorouracil (5FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5FU and cisplatin (HLFP regimen) for metastatic oesophageal cancer. Eur. J. Cancer 38 (2002) 661-666
42. Reni M., Cordio S., Milandri C., Passoni P., Bonetto E., Oliani C., Luppi G., Nicoletti R., Galli L., and Bordonaro R. Gemcitabine versus cisplatin, epirubicin, 5-fluorouracil, gemcitabine in advanced pancreatic cancer: a phase III trial. Lancet Oncol. 6 (2005) 369-376
43. Tajiri H., Yoshimori M., Okazaki N., and Miyaji M. Phase II study of continuous venous infusion of 5-fluorouracil in advanced pancreatic cancer. Oncology 48 (1991) 18-21
44. Ducreux M., Rougier P., Pignon J.P., Douillard J.-Y., Seitz J.-F., Bugat R., Bosset J.-F., Merouche Y., Raoul J.-L., Ychou M., Adenis A., Berthault-Cvitkovic F., and Luboinski M. A randomized trial comparing 5FU with 5FU plus cisplatin in advanced pancreatic carcinoma. Ann. Oncol. 13 (2002) 1185-1191
45. Reni M., Passoni P., Panucci M.G., Nicoletti R., Galli L., Balzano G., Zerbi A., Di Carlo V., and Villa E. Definitive results of a phase II trial of PEF-G (cisplatin, epirubicin, 5-fluorouracil continuous infusion, gemcitabine) in stage IV pancreatic adenocarcinoma. J. Clin. Oncol. 19 (2001) 2679-2686
46. Bleiberg H., Conroy T., Paillot B., Lacave A.J., Blijham G., Jacob J.H., Bedenne L., Namer M., De Besi P., Gay F., Collette L., and Sahmoud T. Randomised phase II study of cisplatin and 5-fluorouracil (5FU) versus cisplatin alone in advanced squamous-cell oesophageal cancer. Eur. J. Cancer 33 (1997) 1216-1220
47. Rougier P., Bugat R., Douillard J.Y., Culine S., Suc E., Brunet P., Becouarn Y., Ychou M., Marty M., Extra J.M., Bonneterre J., Adenis A., Seitz J.F., Ganem G., Namer M., Conroy T., Negrier S., Merrouche Y., Burki F., Mousseau M., Herait P., and Mahjoubi M. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy- naive patients and patients pretreated with fluorouracil based chemotherapy. J. Clin. Oncol. 15 (1997) 251-260
48. Van Cutsem E., Pozzo C., Starkhammer H., Dirix L., Terzoli E., Cognetti F., Humblet Y., Garufi C., Filez L., Gruia G., Cote C., and Barone C. A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer. Ann. Oncol. 9 (1998) 1199-1204
49. de Lima P.D., Cardoso P.C., Khayat A.S., Bahia M.O., and Burbano R.R. Evaluation of the mutagenic activity of hydroxyurea on the G1-S-G2 phases of the cell cycle: an invitro study. Genet. Mol. Res. 2 (2003) 328-333
50. Hutter M.C. Stability of the guanine-cytosine radical cation in DNA base pairs triplets. Chem. Phys. 326 (2006) 240-245
51. Goodman M.F., Creighton S., Bloom L.B., and Petruska J. Biochemical basis of DNA replication fidelity. J. Crit. Rev. Biochem. Mol. Biol. 28 (1993) 83-126
52. Leonard G.A., Booth E.D., and Brown T. Structural and Thermodynamic studies on the adenine guanine mismatch in B-dna. Nucleic Acids Res. 18 (1990) 5617-5623
53. Plum G.E., Grollman A.P., Johnson F., and Breslauer K.J. Influence of the oxidatively damaged adduct 8 deoxyguanosine on the conformation, energetics, and thermodynamc stability of a DNA duplex. Biochemistry 34 (1995) 16148-16160
54. Hoeijmakers J.H.J. Genome maintanence mechanisms for preventing cancer. Nature 411 (2001) 366-374
55. Li V.S., Choi D., Wang Z., Jimenez L.S., Tang M.S., and Kohn H. Role of the C-10 Substituent in Mitomycin C-1-DNA Bonding. J. Am. Chem. Soc. 118 (1996) 2326-2331
56. Tomasz M., Lipman R., Chowdary D., Pawlak J., Verdine G.L., and Nakanishi K. Isolation and structure of a covalent cross-link adduct between mitomycin C and DNA. Science 235 (1987) 1204-1208
57. Hecht S.M. Bleomycin: new perspectives on the mechanism of action1. J. Nat. Prod. 63 (2000) 158-168
58. Zuber G., Quada J.C., and Hecht S.M. Sequence selective cleavage of a DNA octanucleotide by chlorinated bithiazoles and bleomycins. J. Am. Chem. Soc. 120 (1998) 9368-9369
59. 2: luminescent metal complexes that bind DNA base mismatches. Inorg. Chem. 43 (2004) 4570-4578
60. Gu J., Wang J., and Leszczynski J. H-bonding patterns in the platinated guanine-cytosine base pair and guanine-cytosine-guanine-cytosine base tetrad: an electron density deformation analysis and AIM study. J. Am. Chem. Soc. 126 (2004) 12651-12660
61. Sponer J., Sabat M., Burda J.V., Leszczynski J., Hobza P., and Lippert B. Metal ions in non-complementary DNA base pairs: an ab initio study of Cu(I), Ag(I), and Au(I) complexes with the cytosine-adenine base pair. J. Biol. Inorg. Chem. 4 (1999) 537-545
62. Faibis V., Cognet J.A.H., Boulard Y., Sowers L.C., and Fazakerley G.V. Solution structure of two mismatches G_G and I_I in the K-ras gene context by nuclear magnetic resonance and molecular dynamics. Biochem. 35 (1996) 14452-14464
63. Borden K.L.B., Jenkins T.C., Skelly J.V., Brown T., and Lane A.N. Conformational properties of the G_G mismatch in d(CGCGAATTGGCG)2 determined by NMR. Biochem. 31 (1992) 5411-5422
64. Cognet J.A.H., Gabarro-Arpa J., LeBret M., Van der Marel G.A., Boom J.H., and Fazakerley G.V. Solution conformation of an oligonucleotide containing a G.G mismatch determined by nuclear magnetic resonance and molecular mechanics. Nucleic Acids Res. 19 (1991) 6771-6779
65. Gervais V., Cognet J.A.H., LeBret M., Sowers L.C., and Fazakerley G.V. Solution structure of two mismatches A_A and T_T in the K-ras gene context by nuclear magnetic resonance and molecular dynamics. Eur. J. Biochem. 228 (1995) 279-290
66. Maskos K., Gunn B.M., LeBlanc D.A., and Morden K.M. NMR study of G.A and A.A pairing in d(GCGAATAAGCG)2. Biochemistry 32 (1993) 3583-3595
67. Arnold F.H., Wolk S., Cruz P., and Tinoco I.J. Structure, dynamics, and thermodynamics of mismatched DNA oligonucleotides duplexes d(CCCAGGG)2 and d(CCCTGGG). Biochemistry 26 (1987) 4068-4075
68. Boulard Y., Cognet J.A.H., and Fazakerley G.V. Solution structure as a function of pH of two central mismatches, C ́T and C ́C, in the 29 to 39 K-ras gene sequence, by nuclear magnetic resonance and molecular dynamics. J. Mol. Biol. 268 (1997) 331-347
69. Peyret P., Seneviratne A., Allawi H.T., and SantaLucia Jr. J. Nearest-neighbor thermodynamics and NMR of DNA sequences with internal A ́A, C ́C, G ́G, and T ́T mismatches. Biochemistry 38 (1999) 3468-3477
70. Becke A.D. Density - functional exchange-energy approximation with correct asymptotic behavior. Phys. Rev., A 38 (1988) 3098-3100
71. Lee C., Yang W., and Parr R.G. Development of the corre-salvetti correlation energy formula into a functional of the electron density. Phys. Rev., B 37 (1988) 785-789
72. Boys S.F., and Bernardi F. The calculation of small molecular interactions by the differences of separate total energies. Some procedures with reduced errors. Mol. Phys. 19 (1970) 553-566
73. Xantheas S.S. On the importance of the fragment relaxation energy terms in the estimation of the basis set superposition error correction to the intermolecular interaction energy. J. Chem. Phys. 104 (1996) 8821
74. MORPHY98. A Program Written by P.L.A. Popelier with a contribution from R.G.A. Bone (1998), UMIST, Manchester, England, EU
75. E.D. Gledening, A.E. Reed, J.A. Carpenter, F. Weinhold, NBO Version 3.1, 1980.
76. Frisch M.J., Trucks G.W., Schlegel H.B., Scuseria G.E., Robb M.A., Cheeseman J.R., Zakrzewski V.G., Montgomery Jr. J.A., Stratmann R.E., Burant J.C., Dapprich S., Millam J.M., Daniels A.D., Kudin K.N., Strain M.C., Farkas O., Tomasi J., Barone V., Cossi M., Cammi R., Mennucci B., Pomelli C., Adamo C., Clifford S., Ochterski J., Petersson G.A., Ayala P.Y., Cui Q., Morokuma K., Malick D.K., Rabuck A.D., Raghavachari K., Foresman J.B., Cioslowski J., Ortiz J.V., Baboul A.G., Stefanov B.B., Liu G., Liashenko A., Piskorz P., Komaromi I., Gomperts R., Martin R.L., Fox D.J., Keith T., Al-Laham M.A., Peng C.Y., Nanayakkara A., Gonzales C., Challacombe M., Gill P.M.W., Johnson B., Chen W., Wong M.W., Andres J.L., Gonzalez C., Head-Gordon M., Replogle E.S., and Pople J.A. Gaussian 03. Revision A.11. 2 (2005), Gaussian, Inc., Pittsburgh PA
77. Hobza P., and Sponer J. Structure, energetics, and dynamics of the nucleic acid base pairs: nonempirical ab initio calculations. Chem. Rev. 99 (1999) 3247-3276
78. Goldwasser F., Shimizu T., Jackman J., Hoki Y., Connor P.M.O., Kohn K.W., and Pommier Y. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res. 56 (1996) 4430-4437
79. Boger D.L., and Garbaccio R.M. Catalysis of the CC-1065 and Duocarmycin DNA alkylation reaction DNA binding induced conformational change in the agent results in Activation. Bioorg. Med. Chem. 5 (1997) 263-276
80. Sun D., Lin C.H., and Hurley L.H. A-Tract and (+)-cc-1065-induced binding of DNA comparision of structural features using non-denaturing gel analysis, hydroxyl radical foot printing, and high-field NMR. Biochemistry 32 (1993) 4487-4495
81. Schnell J.R., Ketchem R.R., Boger D.L., and Charzin W.J. Binding-induced activation of DNA alkylation by Duocarmycin SA: insights from the structure of an indole derivative-DNA adduct. J. Am. Chem. Soc. 121 (1999) 5645-5652